Exenatide (exendin-4)-induced pancreatitis: a case report.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Diabetes Care

• Publication date

  2006-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/DIACARE.29.02.06.DC05-2043PMID 16443920
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.

  2005cited by this paper

• Unraveling the safety profile of GLP-1 receptor agonists: Mechanistic insights with a focus on semaglutide.

  2025cites this paper
• Pancreatitis Risk Associated with GLP-1 Receptor Agonists, Considered as a Single Class, in a Comorbidity-Free Subgroup of Type 2 Diabetes Patients in the United States: A Propensity Score-Matched Analysis

  2025cites this paper
• The hypoglycemic and antioxidant potential of the methanolic extract from Eucomis autumnalis (Mill.) Chitt leaves: an in vitro and in silico investigation

  2025cites this paper
• Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning

  2025cites this paper
• The potential adverse effects of hypodermic glucagon‐like peptide ‐1 receptor agonist on patients with type 2 diabetes: A population‐based study

  2024cites this paper
• Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis

  2024cites this paper
• Diuretics-Induced Acute Pancreatitis: Case Series with a Review of the Literature.

  2024cites this paper
• Incretin mimetics and acute pancreatitis: enemy or innocent bystander?

  2024cites this paper
• GLP-1RA Essentials in Gastroenterology: Side Effect Management, Precautions for Endoscopy and Applications for Gastrointestinal Disease Treatment

  2024cites this paper
• Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the FDA Adverse Event Reporting System and literature visualization analysis

  2023cites this paper
• To explore the putative molecular targets of Diabetic Nephropathy and their inhibition utilizing potential phytocompounds.

  2023cites this paper
• Efficacy and tolerability of the Subcutaneous Semaglutide for type 2 Diabetes patients: an updated systematic review and meta-analysis

  2023cites this paper
• Multivalent γ‐PGA‐Exendin‐4 Conjugates to Target Pancreatic β‐Cells

  2022cites this paper
• Tirzepatide—Friend or Foe in Diabetic Cancer Patients?

  2022cites this paper
• Adverse drug reactions of GLP-1 agonists: A systematic review of case reports.

  2022cites this paper
• Opinion on the Use of Animal Models in Nonclinical Safety Assessment: Pros and Cons

  2021cites this paper
• Pancreatic Safety of Once-Weekly Dulaglutide in Chinese Patients with Type 2 Diabetes Mellitus: Subgroup Analysis by Potential Influencing Factors

  2021cites this paper
• Drug induced pancreatitis: A systematic review of case reports to determine potential drug associations

  2020cites this paper
• Glucagon-like peptide-1 suppresses neuroinflammation and improves neural structure.

  2019cites this paper
• Multivalent activation of GLP-1 and sulfonylurea receptors modulates β-cell second-messenger signaling and insulin secretion.

  2019cites this paper
• The relationship between HbA1c and microalbuminuria in type II diabetic patients in Isfahan province

  2019cites this paper
• Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity.

  2019cites this paper
• Colitis reducing effects of Lactobacillus plantarum YS-4 in dextran sulfate sodium-induced C57BL/6J mice

  2018cites this paper
• Exendin-4 dose not evoke pancreatitis or pancreatitis-associated histopathological and genetic changes in high-fat diet induced diabetic mice

  2018cites this paper
• THE IMPACT OF DEGRADATION INHIBITOR OF GLUCAGON LIKE POLYPEPTIDE 1 ON BODY WEIGHT AND BETA-CELL FUNCTION IN OBESE WOMEN WITH POLYCYSTIC OVARIAN SYNDROME

  2018cites this paper
• Incretin Therapies Do Not Expand &bgr;-Cell Mass or Alter Pancreatic Histology in Young Male Mice

  2017cites this paper
• Quantitative Testing of Prescriber Knowledge Regarding the Risks and Safe Use of Albiglutide

  2017cites this paper
• Gastrointestinal and Cardiovascular Effects of Incretin-Based Therapies: Friend or Foe?

  2017cites this paper
• Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide

  2017cites this paper
• Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial

  2016cites this paper
• Liraglutide effect and action in diabetes-In (LEAD-In): A prospective observational study assessing safety and effectiveness of liraglutide in patients with type 2 diabetes mellitus treated under routine clinical practice conditions in India

  2016cites this paper
• Toxicology Assessment of a Dual-Function Peptide 5rolGLP-HV in Mice

  2016cites this paper
• Improved β-Cell Targeting and Therapeutics Using Multivalent Glucagon-Like Peptide-1 (GLP-1) Linked to the α2AR Antagonist Yohimbine (YHB): Evaluating the Binding, Selectivity and Signaling

  2016cites this paper
• Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin‐based therapies

  2016cites this paper
• Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: A Long March to Therapeutic Successes

  2016cites this paper
• Development of GLP-1 secretagogue using microarray in enteroendocrine L cells

  2016cites this paper
• Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program

  2016cites this paper
• Potential side effects to GLP-1 agonists: understanding their safety and tolerability

  2015cites this paper
• Drug-induced acute pancreatitis: a review.

  2015cites this paper
• Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients

  2015cites this paper
• Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients

  2015cites this paper
• Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients

  2015cites this paper
• Using real‐world data to evaluate the association of incretin‐based therapies with risk of acute pancreatitis: a meta‐analysis of 1 324 515 patients from observational studies

  2015cites this paper
• Incretin System: Recent Advances in Glucagon Like Peptide-1 and Dipeptidyl Peptidase-4 Inhibitors

  2015cites this paper
• A porcine type 1 Diabetes Mellitus model, for non-invasive in vivo imaging of the glucagon-like peptide-1 receptor in the pancreas, using [68Ga]Ga-DO3A-VS-Cys40-conjugated synthetic exendin-4 in PET-CT

  2015cites this paper
• Antidiabetic therapy in post kidney transplantation diabetes mellitus.

  2015cites this paper
• Exendin-4, a glucagon-like peptide-1 receptor agonist, inhibits Aβ25-35-induced apoptosis in PC12 cells by suppressing the expression of endoplasmic reticulum stress-related proteins.

  2015cites this paper
• Sitagliptin increases acute pancreatitis risk within 2 years of its initiation: A retrospective cohort analysis of the National Health Insurance database in Taiwan

  2015cites this paper
• Management of Glycemia in Diabetic Patients with Stage IV and V Chronic Kidney Disease

  2015cites this paper
• An Investigative Study of Pancreatic Exocrine Biomarkers, Histology, and Histomorphometry in Male Zucker Diabetic Fatty (ZDF) Rats Given Dulaglutide by Subcutaneous Injection Twice Weekly for 13 Weeks

  2015influential citation
• Effects of the GLP-1 Receptor Agonist Dulaglutide on the Structure of the Exocrine Pancreas of Cynomolgus Monkeys

  2015cites this paper
• The nonhuman primate as a model for type 2 diabetes

  2014cites this paper
• The glucagon‐like peptide‐1‐based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys

  2014cites this paper
• Health Sciences Research Commons

  2014cites this paper
• Evaluation of miR-216a and miR-217 as potential biomarkers of acute pancreatic injury in rats and mice

  2014cites this paper
• Drug induced acute pancreatitis: does it exist?

  2014cites this paper
• Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance

  2014cites this paper
• Divergent Effects of Liraglutide, Exendin-4, and Sitagliptin on Beta-Cell Mass and Indicators of Pancreatitis in a Mouse Model of Hyperglycaemia

  2014influential citation
• Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry.

  2014cites this paper
• Autophagy in Pancreatic Acinar Cells in Caerulein-treated Mice

  2014cites this paper
• Adverse Effects of GLP-1 Receptor Agonists.

  2014cites this paper
• Balancing Benefits and Risks in Patients Receiving Incretin-Based Therapies: Focus on Cardiovascular and Pancreatic Side Effects

  2014cites this paper
• Glucagon-like peptide-1 in nonalcoholic steatohepatitis

  2014cites this paper
• Antihyperglycaemic therapies and cancer risk

  2014cites this paper
• Chapter 42 - Insulin, other hypoglycemic drugs, and glucagon

  2014cites this paper
• Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner.

  2014cites this paper
• LEADER 3—Lipase and Amylase Activity in Subjects With Type 2 Diabetes

  2014cites this paper
• High fat diet and GLP-1 drugs induce pancreatic injury in mice.

  2014cites this paper
• Is there a place for incretin therapies in obesity and prediabetes?

  2013cites this paper
• Guideline Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes

  2013cites this paper
• Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies

  2013cites this paper
• Acting on Hormone Receptors with Minimal Side Effect on Cell Proliferation: A Timely Challenge Illustrated with GLP-1R and GPER

  2013cites this paper
• The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database

  2013cites this paper
• The Effects of Dipeptidyl-Peptidase-IV Inhibitor, Vildagliptin, on the Exocrine Pancreas in Spontaneously Diabetic Goto-Kakizaki Rats

  2013cites this paper
• Incretin-Based Therapies: Facing the Realities of Benefits Versus Side Effects

  2013cites this paper
• Systems Pharmacology of Adverse Event Mitigation by Drug Combinations

  2013cites this paper
• Simvastatin-Induced Acute Pancreatitis: A rare side effect of a statin

  2013cites this paper
• Incretin-based therapies in the treatment of type 2 diabetes--more than meets the eye?

  2013cites this paper
• GLP-1R agonist may activate pancreatic stellate cells to induce rat pancreatic tissue lesion.

  2013cites this paper
• Use of Glucagon-Like Peptide-1 Agonists to Improve Islet Graft Performance

  2013cites this paper
• Combinatorial Targeting of the Glucagon-Like Peptide-1 And Sulfonylurea-1 Receptors Using a Complimentary Multivalent Glucagon-Like Peptide-1/Glibenclamide Ligand for the Improvement of β-Cell Targeting Agents and Diabetic Treatment

  2013cites this paper
• Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes

  2013cites this paper
• A pooled analysis of exenatide use and risk of acute pancreatitis

  2013cites this paper
• Enteroendocrine hormone mimetics for the treatment of obesity and diabetes.

  2013cites this paper
• Los nuevos antidiabéticos en el punto de mira… ¿razones de seguridad o caza de brujas?

  2012cites this paper
• GLP1 and cancer: friend or foe?

  2012cites this paper
• The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis.

  2012cites this paper
• Novel Pharmacological Approaches to the Treatment of Type 2 Diabetes

  2012cites this paper
• Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials

  2012cites this paper
• Diabetes or Diabetes Drugs: A Cause for Acute Pancreatitis

  2012cites this paper
• Effect of exendin (exenatide)--GLP 1 receptor agonist on the thyroid and parathyroid gland in a rat model.

  2012cites this paper
• Pancreatitis: A Potential Complication of Liraglutide?

  2012cites this paper
• DRUG-INDUCED PANCREATITIS …OR NOT?

  2012influential citation
• [The new antidiabetic agents in the firing line.... safety reasons or witch hunt?].

  2012cites this paper
• The Human GLP-1 Analog Liraglutide and the Pancreas

  2012cites this paper
• The new antidiabetic agents in the firing line… safety reasons or witch hunt?

  2012cites this paper
• Exenatide Therapy and the Risk of Pancreatitis and Pancreatic Cancer in a Privately Insured Population

  2012cites this paper
• Inkretinová léčba a riziko akutní pankreatitidy

  2012cites this paper
• Exenatide-Induced Chronic Damage of Pancreatic Tissue in Rats

  2012cites this paper
• Effects of a Glucagon-like Peptide-1 Mimetic ( Exenatide ) in Healthy Cats

  2012cites this paper